losartan has been researched along with Autoimmune Diabetes in 53 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbuminuria in normotensive Type 1 diabetes mellitus, 16 subjects with Type 1 diabetes were randomly assigned to two 2-month treatment periods, with either losartan (25 mg/day) or enalapril (5 mg/day) in a single-blind cross-over design." | 9.09 | Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects. ( Açbay, O, 2001) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 7.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "Angioedema and cough are known side effects of angiotensin-converting enzyme (ACE) inhibitors." | 5.31 | Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. ( Abdi, R; Dong, VM; Lee, CJ; Ntoso, KA, 2002) |
| "We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years." | 5.14 | Renal and retinal effects of enalapril and losartan in type 1 diabetes. ( Donnelly, S; Drummond, K; Gardiner, R; Goodyer, P; Gubler, MC; Klein, R; Mauer, M; Sinaiko, A; Strand, T; Suissa, S; Zinman, B, 2009) |
| " We investigated whether this polymorphism is predictive of reductions in blood pressure and albuminuria and preservation of glomerular filtration rate (GFR) during short-term and long-term treatment with losartan in 57 hypertensive type-1 diabetic patients with diabetic nephropathy." | 5.12 | Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. ( Andersen, S; Lajer, M; Parving, HH; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbuminuria in normotensive Type 1 diabetes mellitus, 16 subjects with Type 1 diabetes were randomly assigned to two 2-month treatment periods, with either losartan (25 mg/day) or enalapril (5 mg/day) in a single-blind cross-over design." | 5.09 | Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects. ( Açbay, O, 2001) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 3.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "After 12 weeks of the treatment with losartan, albuminuria was reduced from baseline by 9% [95% confidence interval (CI): 1-17, p = 0." | 3.76 | Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. ( Ajdinović, B; Andelković, Z; Dragović, T; Hrvacević, R; Ilić, V; Kocev, N; Magić, Z, 2010) |
| " Losartan improved both the diabetes-related abnormalities and the diabetic hypertension." | 3.74 | Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nogami, T; Taguchi, K, 2008) |
| "Treatment with losartan potassium or enalapril maleate was not associated with a statistically significant change in CRAE or CRVE." | 2.75 | Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. ( Donnelly, SM; Gardiner, R; Goodyer, P; Klein, BE; Klein, R; Mauer, M; Myers, CE; Sinaiko, AR; Strand, T; Suissa, S; Zinman, B, 2010) |
| "Diabetic retinopathy was determined by masked grading of 30 degrees color stereoscopic fundus photographs of 7 standard fields using the Early Treatment Diabetic Retinopathy Study severity scale." | 2.72 | The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. ( Donnelly, SM; Gardiner, R; Goodyer, P; Klein, R; Kramer, MS; Mauer, M; Moss, SE; Sinaiko, AR; Strand, T; Suissa, S; Zinman, B, 2006) |
| "Nine IDDM patients with microalbuminuria (30-300 mg/24 h) were studied." | 2.70 | Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. ( Buter, H; de Jong, PE; de Zeeuw, D; Dullaart, RP; Navis, G, 2001) |
| "The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min." | 2.42 | Losartan in diabetic nephropathy. ( Perico, N; Remuzzi, G; Ruggenenti, P, 2004) |
| "Type 1 diabetes was induced by a single 60 mg/kg intraperitoneal injection of streptozotocin in Sprague-Dawley rats." | 1.48 | A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats. ( Bae, YS; Cha, DR; Dorotea, D; Ha, H; Kwon, G; Lee, JH; Lee, SJ; Moon, SH; Saunders, E, 2018) |
| "The AKT-mTOR pathway is activated in diabetic nephropathy." | 1.39 | Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy. ( Daphnis, E; Ganotakis, E; Giannakakis, K; Katsarou, T; Mavroeidi, V; Papavasiliou, S; Perakis, K; Petrakis, I; Stratigis, S; Stylianou, K; Vardaki, E, 2013) |
| "Losartan treatment (100 mg/day) reduced urinary KIM-1 by 43% over a 12-month period." | 1.37 | Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. ( Andersen, S; Hess, G; Nielsen, SE; Parving, HH; Rossing, P; Zdunek, D, 2011) |
| "Angioedema and cough are known side effects of angiotensin-converting enzyme (ACE) inhibitors." | 1.31 | Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. ( Abdi, R; Dong, VM; Lee, CJ; Ntoso, KA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.66) | 18.2507 |
| 2000's | 31 (58.49) | 29.6817 |
| 2010's | 18 (33.96) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Buhur, A | 1 |
| Gürel, Ç | 1 |
| Kuşçu, GC | 1 |
| Yiğittürk, G | 1 |
| Oltulu, F | 1 |
| Karabay Yavaşoğlu, NÜ | 1 |
| Uysal, A | 1 |
| Yavaşoğlu, A | 1 |
| Chmiel-Perzyńska, I | 1 |
| Perzyński, A | 1 |
| Olajossy, B | 1 |
| Gil-Kulik, P | 1 |
| Kocki, J | 1 |
| Urbańska, EM | 1 |
| Dorotea, D | 1 |
| Kwon, G | 1 |
| Lee, JH | 1 |
| Saunders, E | 1 |
| Bae, YS | 1 |
| Moon, SH | 1 |
| Lee, SJ | 1 |
| Cha, DR | 1 |
| Ha, H | 1 |
| Mavroeidi, V | 1 |
| Petrakis, I | 1 |
| Stylianou, K | 1 |
| Katsarou, T | 1 |
| Giannakakis, K | 1 |
| Perakis, K | 1 |
| Vardaki, E | 1 |
| Stratigis, S | 1 |
| Ganotakis, E | 1 |
| Papavasiliou, S | 1 |
| Daphnis, E | 1 |
| Montanari, A | 1 |
| Pelà, G | 1 |
| Musiari, L | 1 |
| Crocamo, A | 1 |
| Boeti, L | 1 |
| Cabassi, A | 1 |
| Biggi, A | 1 |
| Cherney, DZ | 2 |
| Zinman, B | 6 |
| Kennedy, CR | 1 |
| Moineddin, R | 1 |
| Lai, V | 1 |
| Yang, S | 1 |
| Miller, JA | 2 |
| Prokopec, SD | 1 |
| Boutros, PC | 1 |
| Scholey, JW | 1 |
| Reich, HN | 1 |
| Robiner, WN | 1 |
| Strand, TD | 2 |
| Mauer, M | 6 |
| Komers, R | 2 |
| Xu, B | 1 |
| Fu, Y | 1 |
| McClelland, A | 1 |
| Kantharidis, P | 1 |
| Mittal, A | 1 |
| Cohen, HT | 1 |
| Cohen, DM | 1 |
| Ezel, T | 1 |
| Kocyigit, Y | 1 |
| Deveci, E | 1 |
| Atamer, Y | 1 |
| Sermet, A | 1 |
| Uysal, E | 1 |
| Aktaş, A | 1 |
| Yavuz, D | 1 |
| Kobayashi, T | 1 |
| Nogami, T | 1 |
| Taguchi, K | 1 |
| Matsumoto, T | 1 |
| Kamata, K | 1 |
| Gardiner, R | 4 |
| Suissa, S | 4 |
| Sinaiko, A | 2 |
| Strand, T | 3 |
| Drummond, K | 1 |
| Donnelly, S | 1 |
| Goodyer, P | 3 |
| Gubler, MC | 1 |
| Klein, R | 5 |
| Myers, CE | 1 |
| Klein, BE | 1 |
| Sinaiko, AR | 3 |
| Donnelly, SM | 3 |
| Naviglio, S | 1 |
| Pirozzi, F | 1 |
| Dragović, T | 1 |
| Ajdinović, B | 1 |
| Hrvacević, R | 1 |
| Ilić, V | 1 |
| Magić, Z | 1 |
| Andelković, Z | 1 |
| Kocev, N | 1 |
| Sjølie, AK | 1 |
| Dodson, P | 1 |
| Hobbs, FR | 1 |
| Nielsen, SE | 1 |
| Andersen, S | 9 |
| Zdunek, D | 1 |
| Hess, G | 1 |
| Parving, HH | 9 |
| Rossing, P | 7 |
| Harindhanavudhi, T | 1 |
| Caramori, ML | 1 |
| Demová, H | 1 |
| Cerná, M | 1 |
| Lo, CS | 1 |
| Liu, F | 1 |
| Shi, Y | 1 |
| Maachi, H | 1 |
| Chenier, I | 1 |
| Godin, N | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Zhang, SL | 1 |
| Chan, JS | 1 |
| Yousif, MH | 1 |
| Dhaunsi, GS | 1 |
| Makki, BM | 1 |
| Qabazard, BA | 1 |
| Akhtar, S | 1 |
| Benter, IF | 1 |
| Zhang, L | 1 |
| Xiong, XQ | 1 |
| Fan, ZD | 1 |
| Gan, XB | 1 |
| Gao, XY | 1 |
| Zhu, GQ | 1 |
| Abdi, R | 1 |
| Dong, VM | 1 |
| Lee, CJ | 1 |
| Ntoso, KA | 1 |
| Jacobsen, P | 1 |
| Tarnow, L | 7 |
| Juhl, TR | 2 |
| Drummond, KN | 1 |
| Kramer, MS | 2 |
| Cambien, F | 1 |
| Deinum, J | 1 |
| Bramlage, P | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Dikow, R | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Nielsen, S | 2 |
| Lihn, AS | 1 |
| ØStergaard, T | 1 |
| Mogensen, CE | 2 |
| Schmitz, O | 2 |
| Simkova, R | 1 |
| Kazdova, L | 1 |
| Ruzickova, J | 1 |
| Pelikanova, T | 1 |
| Perico, N | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Schjoedt, KJ | 2 |
| van Nieuwenhoven, FA | 1 |
| Rossing, K | 1 |
| Wieten, L | 1 |
| Goldschmeding, R | 1 |
| Kim, MJ | 1 |
| Lee, DH | 1 |
| Park, DB | 1 |
| Kang, HW | 1 |
| An, CS | 1 |
| Cui, XJ | 1 |
| Kang, JS | 1 |
| Kim, JL | 1 |
| Lee, YJ | 1 |
| Jung, KW | 1 |
| Baumgart, P | 1 |
| Lajer, M | 2 |
| Moss, SE | 1 |
| Chipitsyna, G | 1 |
| Gong, Q | 1 |
| Gray, CF | 1 |
| Haroon, Y | 1 |
| Kamer, E | 1 |
| Arafat, HA | 1 |
| Nuwayri-Salti, N | 1 |
| Karam, CN | 1 |
| Al Jaroudi, WA | 1 |
| Usta, JA | 1 |
| Maharsy, WM | 1 |
| Bitar, KM | 1 |
| Bikhazi, AB | 1 |
| de Cavanagh, EM | 1 |
| Ferder, L | 1 |
| Toblli, JE | 1 |
| Piotrkowski, B | 1 |
| Stella, I | 1 |
| Fraga, CG | 1 |
| Inserra, F | 1 |
| Arrick, DM | 1 |
| Sharpe, GM | 1 |
| Sun, H | 1 |
| Mayhan, WG | 1 |
| Cohen, LS | 1 |
| Friedman, EA | 1 |
| Ottlecz, A | 1 |
| Bensaoula, T | 1 |
| Eichberg, J | 1 |
| Peterson, RG | 1 |
| Hansen, BV | 1 |
| Schalkwijk, CG | 1 |
| Stehouwer, CD | 1 |
| Buter, H | 2 |
| van Tol, A | 1 |
| Navis, GJ | 1 |
| Scheek, LM | 1 |
| de Jong, PE | 2 |
| de Zeeuw, D | 2 |
| Dullaart, RP | 2 |
| Collis, J | 1 |
| Cheetham, C | 1 |
| Dembo, L | 1 |
| O'Driscoll, J | 1 |
| Stanton, K | 1 |
| Taylor, R | 1 |
| Green, D | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Abe, A | 1 |
| Imasawa, T | 1 |
| Hosoya, T | 1 |
| Matsumura, M | 1 |
| Navis, G | 1 |
| Açbay, O | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Hove, KY | 1 |
| Dollerup, J | 1 |
| Poulsen, PL | 1 |
| Christiansen, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renin Angiotensin System Blockage-DN (RASS)[NCT00143949] | Phase 2 | 285 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure[NCT03371823] | Phase 4 | 8 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to We experienced challenges recruiting unmedicated women with high blood pressure for the intervention.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cutaneous blood flow is measured via laser Doppler flowmetry during cutaneous microdialysis perfusions of ET-A and ET-B receptor antagonists as previously described by Wenner MM in 2017(see reference list). (NCT03371823)
Timeframe: Each participant was assessed at baseline and 2 weeks later.
| Intervention | % change blood flow flux (Mean) | |
|---|---|---|
| ETA blockade | ETB blockade | |
| Normotensive | 437 | 42 |
3 reviews available for losartan and Autoimmune Diabetes
| Article | Year |
|---|---|
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabe | 2004 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
20 trials available for losartan and Autoimmune Diabetes
| Article | Year |
|---|---|
Nitric oxide-angiotensin II interactions and renal hemodynamic function in patients with uncomplicated type 1 diabetes.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Case-Control Studies; Di | 2013 |
Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chemokines | 2013 |
Adherence and renal biopsy feasibility in the Renin Angiotensin-System Study (RASS) primary prevention diabetes trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Biopsy; Diabetes Mellitus, Type 1; Diabetic Nephropathie | 2013 |
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2010 |
Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic | 2011 |
ACE-I and ARBs in early diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Diabetes | 2002 |
Increased plasma adiponectin in losartan-treated type 1 diabetic patients. a mediator of improved insulin sensitivity?
Topics: Adiponectin; Adult; Angiotensin Receptor Antagonists; Blood Glucose; Cross-Over Studies; Diabetes Me | 2004 |
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; | 2004 |
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Melli | 2004 |
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cytochrome P-450 CYP11B | 2006 |
The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pres | 2006 |
Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Cross-Over Studies; Diabete | 1999 |
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Cholesterol; Cholesterol, LDL; Cholesterol, VL | 2000 |
Losartan, an angiotensin type 1 receptor inhibitor, and endothelial vasodilator function in Type 1 diabetes mellitus.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cross-Over Studies; Diabet | 2000 |
Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2001 |
Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, | 2001 |
Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2001 |
30 other studies available for losartan and Autoimmune Diabetes
| Article | Year |
|---|---|
Is losartan a promising agent for the treatment of type 1 diabetes-induced testicular germ cell apoptosis in rats?
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Germ Cells; Losartan | 2023 |
Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2019 |
A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dose-Re | 2018 |
Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Models, Animal; Kidney Glomerulu | 2013 |
Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.
Topics: Amino Acid Transport System y+; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Type 1 | 2014 |
Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dia | 2015 |
Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Experime | 2008 |
Renin-Angiotensin system blockade for diabetic nephropathy prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Typ | 2010 |
Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure | 2010 |
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
Topics: Acute-Phase Proteins; Adult; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fatty Ac | 2011 |
RhoA distribution in renal caveolar fractions in experimental type 1 diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Western; Caveolae; Caveolin 1; Diabetes Mellitu | 2011 |
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enz | 2012 |
Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Captopril; Cardiovascular S | 2012 |
Involvement of enhanced cardiac sympathetic afferent reflex in sympathetic activation in early stage of diabetes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Bradykinin | 2012 |
Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema.
Topics: Adult; Angioedema; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 2003 |
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diabetes | 2003 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Topics: Adult; Connective Tissue Growth Factor; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; G | 2005 |
Chronic blockade of the angiotensin II receptor has a differential effect on adipose and vascular PAI-1 in OLETF rats.
Topics: Adipose Tissue; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Aorta, Thoracic; Diabete | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Chemokine CCL2; | 2007 |
CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy.
Topics: Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mell | 2007 |
Effect of type-1 diabetes mellitus on the regulation of insulin and endothelin-1 receptors in rat hearts.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Type 1; Endothelin-1; Fluorescent Antibody Technique; | 2007 |
Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; | 2008 |
Losartan improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type 1 diabetic rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Cerebral Arteries; Cerebrovascular Dis | 2008 |
Losartan-induced azotemia in a diabetic recipient of a kidney transplant.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
Angiotensin-converting enzyme activity in retinas of streptozotocin-induced and Zucker diabetic rats. The effect of angiotensin II on Na+,K(+)-ATPase activity.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Experimenta | 1996 |
Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C | 2000 |
Mannitol-induced toxicity in a diabetic patient receiving losartan.
Topics: Acute Kidney Injury; Antihypertensive Agents; Diabetes Mellitus, Type 1; Diuretics, Osmotic; Drug Hy | 2001 |